drugset / Trial / NCT06906341
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Timeline
- Start
- 2025-04-11
- Primary completion
- 2026-08
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Subject | Relacorilant | Small molecule | 150 mg | Oral |